I don't know what the composition-of-matter patent life is, but the Alza OROS formulation of the drug undoubtedly has much better patent life than that--I'd have to find old notes from talking with Gallen to recall exactly what--but Covidien (aka Mallinckrodt, was spun out from Tyco) would not have paid $55 million thus far, with all the launch process still to go--if they only had three years to play with.
Market Data 
Markets 
AI
